Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Caspofungin versus amphotericin B deoxycholate for invasive candidiasis in neonates and young infants
2013-002084-26Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Oct 2016
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in invasive candidiasis comparing Caspofungin with Amphotericin B deoxycholate (2 arms). Primary endpoints: Pharmacokinetic profile of caspofungin and Fungal-free survival at 2-week post-therapy follow-up. Started Oct 2016; status: terminated.
02
Drugs
caspofunginamphotericin b deoxycholate
03
Conditions
invasive candidiasis
Beyond the preview
Go deeper on 2013-002084-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002084-26.